Ekso Bionics (EKSO) Proxy Filing summary

Executive summary

• Supplement corrects the year for board member terms from 2024 to 2025 for the upcoming annual meeting.

• No other changes are made to the previously filed proxy statement or notice.

Voting matters and shareholder proposals

• Proposal One is to elect five directors to serve until the 2025 annual meeting and until successors are elected and qualified.

• Correction clarifies the intended term for elected directors, ensuring accurate voting information.

Board of directors and corporate governance

• Five individuals are nominated for election to the board, with terms extending to the 2025 annual meeting.

• Directors will serve until successors are elected or until earlier death, resignation, or removal.